4DMedical Strengthens U.S. Presence with Mayo Clinic Deployment
4DMedical Limited (ASX: 4DX), a company at the forefront of respiratory imaging innovation, has strengthened its footprint in the U.S. market by introducing its CT:VQ™ technology at the Mayo Clinic. This marks the sixth major U.S. Academic Medical Center to adopt the technology within a short period following FDA clearance, highlighting strong commercial traction and increasing clinical acceptance.
CT:VQ™ delivers advanced ventilation and perfusion analysis, offering enhanced imaging capabilities without requiring radioisotopes or contrast agents. Its seamless integration into existing CT workflows improves diagnostic efficiency and supports more precise monitoring of lung diseases.
While the initial agreement is not financially significant, the collaboration carries strong strategic value. Mayo Clinic’s global reputation and influence in clinical practice position it as a critical reference site, which could accelerate broader adoption of the technology.
Overall, this development strengthens 4DMedical’s position as it advances its goal of establishing CT:VQ™ as a new standard in respiratory imaging, supported by a growing commercial pipeline and strategic partnerships.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
4DMedical Strengthens U.S. Presence with Mayo Clinic Deployment
4DMedical Limited (ASX: 4DX), a company at the forefront of respiratory imaging innovation, has strengthened its footprint in the U.S. market by introducing its CT:VQ™ technology at the Mayo Clinic. This marks the sixth major U.S. Academic Medical Center to adopt the technology within a short period following FDA clearance, highlighting strong commercial traction and increasing clinical acceptance.
CT:VQ™ delivers advanced ventilation and perfusion analysis, offering enhanced imaging capabilities without requiring radioisotopes or contrast agents. Its seamless integration into existing CT workflows improves diagnostic efficiency and supports more precise monitoring of lung diseases.
While the initial agreement is not financially significant, the collaboration carries strong strategic value. Mayo Clinic’s global reputation and influence in clinical practice position it as a critical reference site, which could accelerate broader adoption of the technology.
Overall, this development strengthens 4DMedical’s position as it advances its goal of establishing CT:VQ™ as a new standard in respiratory imaging, supported by a growing commercial pipeline and strategic partnerships.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au